Sotac Pharmaceuticals

Sotac Pharmaceuticals Diluted EPS

The Diluted Earnings per Share of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 22, 2026 is 7.26 INR. In the previous year, Diluted Earnings per Share was 3.24 INR — a change of 124.25% (higher).

Diluted EPS

7.26INR

YoY

124.25%

Last updated:

Diluted Earnings per Share of Sotac Pharmaceuticals is 2025 7.26 INR. Diluted Earnings per Share of Sotac Pharmaceuticals was 2024 3.24 INR. It decreases by 124.25% higher compared to the previous year.

The Sotac Pharmaceuticals Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2020
0.08 INR
Jan 1, 2021
-2.14 INR
Jan 1, 2022
2.61 INR
Jan 1, 2023
4.07 INR
Jan 1, 2024
3.24 INR
Jan 1, 2025
7.26 INR
The Sotac Pharmaceuticals Diluted EPS history
YEARDiluted EPSYoY
7.26INR+124.25%
3.24INR-20.38%
4.07INR+56.17%
2.61INR-221.70%
-2.14INR-2,802.78%
0.08INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

Diluted Earnings per Share of Sotac Pharmaceuticals is 7.26 INR in 2025.

Diluted Earnings per Share of Sotac Pharmaceuticals changed from 3.24 INR to 7.26 INR, representing a 124.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sotac Pharmaceuticals

All Key Metrics — Sotac Pharmaceuticals